2025-04-17 - Analysis Report
## Merck & Co Inc (MRK) Stock Review

**0. Executive Summary:**

Merck & Co Inc (MRK) is a leading pharmaceutical company.  While its cumulative return (21.68%) significantly lags behind the S&P 500 (VOO) return (76.08%),  analysis of its recent performance, financial statements, and valuation metrics reveals a mixed picture requiring further investigation.  The company's recent earnings show some variability, and while the stock is currently undervalued relative to the S&P 500, there are indicators suggesting a possible turnaround. The negative expected return and low RSI warrants caution.

**1. Performance Comparison with S&P 500 (VOO):**

Merck & Co Inc (MRK) is a large-cap pharmaceutical company engaged in the research, development, manufacture, and marketing of pharmaceuticals and vaccines.

* **MRK Cumulative Return:** 21.68%
* **VOO (S&P 500) Cumulative Return:** 76.08%
* **Return Difference:** -54.4%
* **Relative Divergence:** 24.2% (This indicates that MRK's underperformance relative to the S&P 500 is in the 24.2nd percentile of its historical range.)

The table below shows the CAGR, maximum drawdown (MDD), alpha, beta, and market capitalization of MRK over various periods:

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 10.0% | 58.6% | -22.0% | 0.1 | 108.6 |
| 2016-2018  | 49.0% | 66.4% | 27.0% | 0.4 | 151.9 |
| 2017-2019  | 48.0% | 66.4% | 14.0% | 0.9 | 185.8 |
| 2018-2020  | 26.0% | 66.4% | -4.0% | 0.7 | 172.4 |
| 2019-2021  | 4.0% | 65.6% | -56.0% | 0.5 | 175.4 |
| 2020-2022  | 20.0% | 69.3% | 11.0% | 0.5 | 262.1 |
| 2021-2023  | 43.0% | 69.3% | 22.0% | 0.3 | 264.8 |
| 2022-2024  | -3.0% | 69.3% | -24.0% | 0.2 | 248.2 |
| 2023-2025  | -48.0% | 70.2% | -62.0% | 0.2 | 192.4 |


The data shows significant volatility in performance and alpha, suggesting inconsistent outperformance relative to the market.  The beta values generally indicate moderate sensitivity to market movements.

**2. Recent Price Movement:**

* **Closing Price:** $76.46
* **Previous Close:** $78.39
* **Change:** -$1.93 (A 2.46% decrease)
* **5-Day Moving Average:** $78.15
* **20-Day Moving Average:** $84.85
* **60-Day Moving Average:** $89.22

The price is below all three moving averages, indicating a downtrend.  The recent price drop is notable.


**3. Technical Indicators and Expected Return:**

* **Market Risk Indicator (MRI):** 0.41 (Medium Risk)
* **RSI:** 27.39 (Oversold territory, suggesting potential for a bounce but not confirming an uptrend)
* **PPO:** -0.98 (Negative value suggests bearish momentum)
* **Relative Strength Change (20-day):** +0.8 (Short-term upward pressure, though this is small considering the overall bearish trend.)
* **Expected Return (2+ years):** -12.0% (This indicates a significant underperformance relative to the S&P 500 is expected over the long term based on the current data. This is a critical red flag.)


The significant price drop (-2.46%) from the previous close needs careful attention. While the short-term indicator shows a slight uptrend, the negative expected return and other indicators suggest further downside risk is possible.

**4. Recent Earnings Analysis:**

| Date       | EPS  | Revenue      |
|------------|------|---------------|
| 2024-11-06 | $1.25 | $16.66 B     |
| 2024-08-05 | $2.15 | $16.11 B     |
| 2024-05-03 | $1.88 | $15.78 B     |
| 2023-11-03 | $1.87 | $15.96 B     |
| 2024-11-06 | $1.87 | $15.96 B     |


There's inconsistency in the EPS figures.  Revenue remains relatively stable but EPS shows substantial variability.  Further investigation is needed to understand the reasons behind this fluctuation.  Duplicate data entry needs to be corrected for accurate analysis.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue    | Profit Margin |
|---------|------------|---------------|
| 2024-12-31 | $15.62B   | 75.50%        |
| 2024-09-30 | $16.66B   | 75.51%        |
| 2024-06-30 | $16.11B   | 76.76%        |
| 2024-03-31 | $15.78B   | 77.56%        |
| 2023-12-31 | $14.63B   | 73.26%        |

**Capital and Profitability:**

| Quarter | Equity     | ROE      |
|---------|------------|----------|
| 2024-12-31 | $46.31B   | 8.08%    |
| 2024-09-30 | $44.50B   | 7.09%    |
| 2024-06-30 | $43.58B   | 12.52%   |
| 2024-03-31 | $40.36B   | 11.80%   |
| 2023-12-31 | $37.58B   | -3.26%   |

Profit margins are consistently high, indicating strong profitability. However, ROE shows significant volatility.  The negative ROE in 2023-12-31 is a cause for concern.


**6. Overall Analysis:**

MRK's current situation is complex. While it boasts high profit margins and a relatively stable revenue stream, its significant underperformance against the S&P 500, negative expected return, and volatile EPS and ROE figures raise serious questions. The oversold RSI suggests potential for a short-term bounce, but the long-term outlook is clouded by the significantly negative expected return and the need for clarification on the reasons behind fluctuating earnings and ROE. A thorough investigation into the recent earnings variability and the drivers of the negative expected return is crucial before making any investment decisions.  The current data suggests a high level of risk.  Further due diligence is strongly advised.
